Cardicomm Solutions, Inc. Press Releases

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), announced today it had closed the second tranche of its previously announced private placement equity financing. Under the closing of the second tranche, the Company issued 600,000 units at a price of $0.05 per unit, for gross proceeds of $30,000. Each unit was comprised of one common share of the Company and one common share purchase warrant...

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it will be conducting a non-brokered private placement equity financing under which it intends to issue up to 5,000,000 units at a price of $0.05 per unit for gross proceeds of up to $250,000. There is no minimum offering amount. Each unit will be comprised of one common share of the Company and one common share purchase warrant...

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today confirmed that its binding letter of intent with Vigilance, Inc., which was previously announced by the Company on June 16, 2014, has been terminated after several rounds of negotiations with the Vigilance Board of Directors failed in developing acceptable terms for entering into a definitive long term working relationship. “As...

Joint Venture will provide CardioComm Solutions with an equity position in Vigilance and recurrent licensing revenues TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions has executed a binding Letter of Intent with Vigilance, Inc. to develop and co-market ECG contract service solution...

Company Remains on Track to Complete $1 Million in Financing in Q1 2014 TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company")announced today it has closed the second tranche of its previously announced private placement equity financing. Under the financing, the Company issued 2,648,000 units at a price of $0.0675 per unit, for gross proceeds of $178,740. Each unit was comprised of one common share of the Company and one common...

HeartCheck™ Technologies to be used to identify people at risk for potentially life-threatening drug side effects TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today announced it has entered into a partnership agreement with the Clinical Neuroendocrinology Laboratory at the University of...

Company Plans to Complete $1 Million in Financing in Q1 2014 TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") announced today it had closed the first tranche of its previously announced private placement equity financing. Under the financing, the Company issued $1,622,222 units at a price of $0.0675 per unit, for gross proceeds of $109,500. Each unit was comprised of one common share of the Company and one common share...

Clearance opens the way for HeartCheck™ Device Sales and SMART Monitoring ECG Services in China TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, confirms that China's Food and Drug Administration ("CFDA") has cleared the HeartCheck™ PEN ECG device and GEMS™ Home software for sale...

Completion of final milestone triggers a third payment and removal of non-completion penalties Toronto, Canada  – CardioComm Solutions, Inc. ( TSX-V:EKG) (“CardioComm Solutions” or the “Company”)today announced it has completed the final milestone of a software and source code licensing agreement ("SLA") for use of the Company's Global ECG Management Solution ("GEMS™") and GUAVA ECG viewer by MD Primer, Inc. ("MDP"), which was previously...

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it has granted 250,000 incentive stock options to Etienne Grima, the Company’s CEO, in accordance with Mr. Grima’s employment agreement. The options are exercisable at $0.055 per share for five years from the date of grant, vest four months from the date of grant and are subject to a four month hold period. The grant...

CardioComm Solutions to begin immediate rollout of GEMS™ for Windows 7 remote ECG analysis, data management software to extensive base of current US health care providers and customers. TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it has granted an aggregate of 500,060 incentive stock options. 250,060 options have been granted to Mr. Etienne Grima, the...

CardioComm Solutions to begin immediate rollout of GEMS™ for Windows 7 remote ECG analysis, data management software to extensive base of current US health care providers and customers. TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and data management software solutions, is pleased to announce it will...

Licensing Deal Signals the Start of Sales of Windows 7 Compatible ECG Software Solutions TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") today announced that it has completed a software and source code licensing agreement ("SLA") for use of the Company's proprietary Global ECG Management Solution ("GEMS™") and GUAVA ECG viewer by MD Primer Inc. ("MDP"). MDP is a clinical research and education organization enabling...

HeartCheck™ Technologies to be used to identify people at risk for potentially life-threatening drug side effects TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it has issued an aggregate of 58,141 common shares of the Company to Simi Grosman, a director of the Company. The shares were issued at a deemed price of $0.095 per share, for a total value of $5,500, as partial...

GUAVA II offers regulatory credibility and efficiency to ECG reading services for physicians and hospitals TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, confirms U.S. Food and Drug Administration (“FDA”) clearance of its GUAVA II ECG viewer technology as a Class II Medical Device. GUAVA II is the...

Arrhythmia Surveillance Utilized HeartCheck™ Device and SMART Monitoring ECG Service Technologies TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company")today announced that it is working within a pilot that uses HeartCheck™ ECG testing technology to support arrhythmia screening and surveillance with long-term care facilities. The pilot was coordinated by Toronto-based In Initiative Inc. and conducted with Responsive...

SMART Monitoring Integration of Reka ECG monitoring device to provide access to new US-based and Global ECG Service Markets TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company")today announced that it has completed a HeartCheck™ and SMART Monitoring distribution and co-marketing agreement ("Agreement") with Reka Health, Inc. (REKA), a US based company. REKA will promote sales of the HeartCheck™ PEN through their...

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company")today announced that an aggregate of 567,460 incentive stock options have been granted to two directors of the Company and to a contractor of the Company. The 417,460 options issued to the directors are exercisable at $0.18 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject...

Ammendment to reflect the new release of GEMS™ WIN as a Windows 7 compatible ECG management software upgrade TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it has amended its GEMS™software license agreement (“SLA”) with MD Primer Inc. (“MDP”), which was previously described by the Company in its press releases on January 22, 2014, and...

Former Executive of ScottCare, CardioNet and Lifewatch Corporation Set to Drive Sales of GEMS? and Mobile Patient Monitoring Solutions into the U.S. Market TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") today announced that Mr. Daniel Pawlik has joined the organization as Vice President, Sales and Marketing for the United States effective January 6, 2014. Mr. Pawlik has held senior executive positions within a number of...

Funding will be used as bridge financing to complete Q1 2014 objectives. TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it will be conducting a non-brokered private placement equity financing under which it intends to issue between 4,166,667 to 8,333,334 units at a price of $0.12 per unit for gross proceeds of $500,000 to $1,000,000.  Each unit will be comprised of one...

Free cardiac arrhythmia surveillance available at no cost to those with a physician prescription. Toronto, Canada – CardioComm Solutions, Inc. (TSX-V:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, announced it shall be providing HeartCheck™  SMART Monitoring ECG services at no cost effective December 10, 2013 for its USA...

Second CIHR and industry sponsored study to use HeartCheck and SMART Monitoring Technologies. Toronto, Canada – CardioComm Solutions, Inc. (TSX-V:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, announced it shall be providing HeartCheckTM  based ECG screening technologies to researchers from the Research Institute of the McGill...

TORONTO, ONTARIO – December 4, 2013. CardioComm Solutions, Inc. (“CardioComm Solutions” or the “Company”) (TSX VENTURE:EKG), a global medical provider of ECG acquisition and management software solutions, today announced that an aggregate of 700,000 incentive stock options have been granted to certain directors of the Company for services rendered in 2013. The options are exercisable at $0.18 per share for five years from the date of grant, vest...

Raytel Cardiac Services will be the first to launch into the American MCT monitoring market using the CardioComm Solutions Wireless Arrhythmia Services Software Toronto, Canada. – CardioComm Solutions Inc. ( TSX-V:EKG) (“CardioComm Solutions” or the “Company”) confirms the release of a custom GEMSTM Mobile Cardiac Telemetry software (“GEMS M-Air”) solution with web-based device interfacing for use by Raytel Cardiac Services Inc....

Rapid physician ECG interpretation services now available to patients, allied health care workers and physician groups. TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm Solutions” or the “Company”) today confirmed it has released a new version of its GEMS Home software to support the prescription model of the HeartCheck™ ECG Monitor. GEMS Home 1.2 is now available at no cost to new and current owners of both the consumer...